Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDA | P32320 | 13/20 | 0.66 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.45 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.45 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.45 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tetrahydrouridine SCHEMBL587704 | 1.00 | CDA (0.66) | CDAMAPTSLC28A1SLC28A2SLC29A1 | |
| Tetrahydrouridine SCHEMBL171865 | 1.00 | CDA (0.66) | CDAMAPTSLC28A1SLC28A2SLC29A1 | |
| Tetrahydrouridine SCHEMBL172272 | 1.00 | CDA (0.66) | CDAMAPTSLC28A1SLC28A2SLC29A1 | |
| Tetrahydrouridine SCHEMBL11761038 | 1.00 | CDA (0.66) | CDAMAPTSLC28A1SLC28A2SLC29A1 | |
| Tetrahydrouridine SCHEMBL11759489 | 1.00 | CDA (0.66) | CDAMAPTSLC28A1SLC28A2SLC29A1 | |
| Tetrahydrouridine SCHEMBL14133787 | 1.00 | CDA (0.66) | CDAMAPTSLC28A1SLC28A2SLC29A1 | |
| SCHEMBL10069547 | 0.87 | CDA (0.59) | CDAMAPT | |
| SCHEMBL12338486 | 0.87 | CDA (0.55) | CDAMAPT | |
| SCHEMBL12338454 | 0.87 | CDA (0.59) | CDAMAPT | |
| SCHEMBL10069752 | 0.87 | CDA (0.59) | CDAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 880 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144879-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | AI-BIOPHARMA (FR) | 2026-05-28 | — | — | US | claimed |
| US-20260076988-A1 | TIMED ALTERNATE ADMINISTRATION OF DECITABINE AND 5-AZACYTIDINE FOR CANCER TREATMENT | CLEVELAND CLINIC FOUND (US) | 2026-03-19 | — | — | US | claimed |
| EP-3976054-B1 | TIMED ADMINISTRATION OF DECITABINE AND 5-AZACYTIDINE FOR CANCER TREATMENT | CLEVELAND CLINIC FOUND (US) | 2026-01-07 | — | — | EP | claimed |
| US-20250313900-A1 | COMPOSITIONS AND THERAPEUTIC AGENTS FOR MODULATING INFLAMMATORY RESPONSES ON BOTH TUMOR AND IMMUNE CELLS | THE METHODIST HOSPITAL | 2025-10-09 | — | — | US | claimed |
| EP-3960182-B1 | COMPOSITIONS CONTAINING DECITABINE, 5-AZACYTIDINE AND TETRAHYDROURIDINE AND USES THEREOF | EPIDESTINY INC (US) | 2025-03-19 | — | — | EP | claimed |
| CN-109789155-B | Composition containing decitabine, 5-azacytidine and tetrahydrouridine and application thereof | 免疫规划公司 | 2025-02-07 | — | — | CN | claimed |
| US-20250000887-A1 | COMPOSITIONS COMPRISING 2'-DEOXYCYTIDINE ANALOGS AND USE THEREOF FOR THE TREATMENT OF SICKLE CELL DISEASE, THALASSEMIA, AND CANCERS | AKIRABIO, INC. (US) | 2025-01-02 | — | — | US | claimed |
| CN-118987233-A | Pharmaceutical composition for treating classical hodgkin lymphoma and application thereof | 武汉科技大学 | 2024-11-22 | — | — | CN | claimed |
| CN-118354759-A | Compositions comprising 2' -deoxycytidine analogs and their use for treating sickle cell disease, thalassemia and cancer | 阿基拉比奥有限公司 | 2024-07-16 | — | — | CN | claimed |
| CN-118302169-A | Methods of treating cancer or hematological disorders | 库泰巴·埃布拉海姆 | 2024-07-05 | — | — | CN | claimed |
| WO-1993001202-A1 | TREATMENT OF CHEMOTHERAPEUTIC AGENT AND ANTIVIRAL AGENT TOXICITY WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO-NEURON, INC. (US) | 1993-01-21 | — | — | WO | claimed |
| US-4990499-A | Treatment of infections and neoplasms | UNIVERSITY OF SASKATCHEWAN (CA) | 1991-02-05 | — | — | US | claimed |
| EP-0160079-B1 | METHOD AND MATERIALS FOR SENSITIZING NEOPLASTIC TISSUE TO RADIATION | GREER, Sheldon B. (US) | 1990-01-31 | — | — | EP | claimed |
| US-4894364-A | ANTITUMOR AGENTS | HALOGENETICS, INC. | 1990-01-16 | — | — | US | claimed |
| EP-0287128-A1 | Antitumor agent | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1988-10-19 | — | — | EP | claimed |
| EP-0160079-A4 | METHOD AND MATERIALS FOR SENSITIZING NEOPLASTIC TISSUE TO RADIATION. | GREER SHELDON B | 1986-05-14 | — | — | EP | claimed |
| EP-0160079-A1 | METHOD AND MATERIALS FOR SENSITIZING NEOPLASTIC TISSUE TO RADIATION. | GREER SHELDON B | 1985-11-06 | — | — | EP | claimed |
| WO-1985001871-A1 | METHOD AND MATERIALS FOR SENSITIZING NEOPLASTIC TISSUE TO RADIATION | GREER SHELDON B | 1985-05-09 | — | — | WO | claimed |
| US-4210638-A | 5-TRIFLUOROMETHYL-2'-DEOXYCYCTIDINE AND TETRAHYDROURIDINE OR 2'-DEOXYTETRAHYDROURIDINE | PCR, INC. (US) | 1980-07-01 | — | — | US | claimed |
| US-4017606-A | CYTOSINE ARABINOSIDE AND HYDROGENATED PYRIMIDINE NUCLEOSIDES | THE UPJOHN COMPANY (US) | 1977-04-12 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250313900-A1 | COMPOSITIONS AND THERAPEUTIC AGENTS FOR MODULATING INFLAMMATORY RESPONSES ON BOTH TUMOR AND IMMUNE CELLS | MIF, CCL2, MPEG1 | CDA 2279/4885MAPT 3195/4885SLC28A1 4185/4885 |
| US-20260144879-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | HAVCR2, NR1H4, NR1H3 | CDA 2500/4885MAPT 4310/4885SLC28A1 74/4885 |
| US-20250000887-A1 | COMPOSITIONS COMPRISING 2'-DEOXYCYTIDINE ANALOGS AND USE THEREOF FOR THE TREATMENT OF SICKLE CELL DISEASE, THALASSEMIA, AND CANCERS | TYMP, HBZ, HBB | CDA 4/4885MAPT 3834/4885SLC28A1 171/4885 |
| US-20260076988-A1 | TIMED ALTERNATE ADMINISTRATION OF DECITABINE AND 5-AZACYTIDINE FOR CANCER TREATMENT | DCTD, ADA, DUT | CDA 4/4885MAPT 4571/4885SLC28A1 776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.